Colorectal cancer (CRC) is the third most common type of cancer and the second leading
cause of cancer deaths worldwide. Surgery or surgery plus radiotherapy and/or …

PURPOSE To develop recommendations for treatment of patients with metastatic colorectal
cancer (mCRC). METHODS ASCO convened an Expert Panel to conduct a systematic …

Genomics has greatly improved how patients with cancer are being treated; however,
clinical-grade genomic biomarkers for chemotherapies are currently lacking. Using whole …

Simple Summary Colorectal cancer (CRC) is a leading cause of death among cancer
patients, and the liver is the most common visceral metastatic site. Despite promising …

To assess the clinical implementation of the 2017 Standards and Guidelines for the
Interpretation and Reporting of Sequence Variants in Cancer: A Joint Consensus …

Colorectal cancer is a sporadic, hereditary, or familial based disease in its origin, caused
due to diverse set of mutations in large intestinal epithelial cells. Colorectal cancer (CRC) is …

Purpose Evaluation of genetic mutations in cancers is important because distinct mutational
profiles help determine individualized drug therapy. However, molecular analyses are not …

Aim Cetuximab and panitumumab are common antibodies against epidermal growth factor
receptor (EGFR) that can be used in combination with chemotherapy for the treatment of …

Purpose Anti-epidermal growth factor receptor (anti-EGFR) monoclonal antibodies are
effective in treating RAS wild-type metastatic colorectal cancer (mCRC). However, their …

In this study we evaluated both~ K-and N-RAS mutations in plasma samples from patients
with metastatic colorectal cancer by means of the BEAMing technology, and we assessed …